Novel intravaginal ring shows promise in HIV prevention

October 16, 2012

A new 90-day intravaginal ring has been developed—that for the first time—enables the long-lasting vaginal delivery of tenofovir (TFV), the only topical prophylactic shown to be effective at reducing the sexual transmission of human immunodeficiency virus (HIV) when formulated in a short-lasting gel. This research is being presented at the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Chicago, Ill., Oct. 14 – 18.

Lead researcher Patrick Kiser and colleagues from the University of Utah, in collaboration with CONRAD, a leading reproductive health research organization, created a novel reservoir ring composed in part of plastic tubing that absorbs water when placed in the body. Conventional ring technology, developed in the 1970s, is inadequate in delivering water-soluble drugs such as TFV. This new design allows for large quantities of TFV to be delivered for up to 90 days, at doses expected to prevent .

"We anticipate that this next-generation ring will be able to release a spectrum of drugs that currently cannot be delivered due to limitations of standard technology," said Kiser, who led development of the ring at the University of Utah. "This ring is a breakthrough design because it is highly adaptable to almost any drug; the amount of drug delivered each day is the same and the release rate can be modified easily if needed."

Kiser's research group shows that the vaginal concentration of TFV in sheep using the new ring is similar to or exceeds that of a short-lasting TFV that was proven to be clinically effective at reducing the risk of in women. This ring can also be readily modified to deliver an anti-HIV agent and a contraceptive at the same time, making it a multi-purpose prevention technology. Work is in progress to do just that, as the group has recently developed a ring to co-deliver TFV and the hormonal contraceptive levonorgestrel (LNG).

Explore further: Anti-HIV vaginal gel promising protection in Africa, SE asia

Related Stories

Anti-HIV vaginal gel promising protection in Africa, SE asia

April 20, 2011

A new vaginal microbicide gel and drug formulation looks promising for empowering women in developing countries to protect themselves from HIV during intercourse, without having to inform their partners, according to research ...

Study of anti-AIDS vaginal ring begins in Africa

July 24, 2012

(AP) — Thousands of women in Africa can volunteer for major new research to see if inserting a vaginal ring coated with an anti-AIDS drug could protect them from HIV infection, U.S. scientists announced Tuesday.

Recommended for you

Targeting HIV in semen to shut down AIDS

August 18, 2015

There may be two new ways to fight AIDS—using a heat shock protein or a small molecule - to attack fibrils in semen associated with the human immunodeficiency virus (HIV) during the initial phases of infection, according ...

HVTN 505 vaccine induced antibodies nonspecific for HIV

July 30, 2015

A study by researchers at the National Institute of Allergy and Infectious Diseases and Duke University helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection ...

Vitamin D status related to immune response to HIV-1

June 15, 2015

Vitamin D plays an important part in the human immune response and deficiency can leave individuals less able to fight infections like HIV-1. Now an international team of researchers has found that high-dose vitamin D supplementation ...

Why HIV's cloak has a long tail

June 2, 2015

Virologists at Emory University School of Medicine, Yerkes National Primate Research Center, and Children's Healthcare of Atlanta have uncovered a critical detail explaining how HIV assembles its infectious yet stealthy clothing.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.